Company profile

Ticker
TMDX
Exchange
CEO
Waleed H. Hassanein
Employees
Incorporated in
Location
Fiscal year end
SEC CIK

TMDX stock data

(
)

Calendar

8 Nov 19
11 Dec 19
28 Dec 19

News

Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Mar 19
Revenue 7.21M 5.67M 4.68M
Net income -8.28M -9.2M -6.9M -6.9M
Diluted EPS -0.39 -0.7 -4.86
Net profit margin -115% -162% -147%
Operating income -7.24M -7.71M -5.96M
Net change in cash -26.84M 35.03M
Cash on hand 20.41M 47.24M 12.22M
Cost of revenue 2.99M 2.33M 2.1M

Financial data from TransMedics earnings reports

Financial report summary

?
Management Discussion
  • Our fiscal year ends on the last Saturday in December, and we report fiscal years using a 52/53-week convention. Under this convention, certain fiscal years contain 53 weeks. Each fiscal year is typically composed of four 13-week fiscal quarters, but in years with 53 weeks, the fourth quarter is a 14-week period. Our fiscal year ended December 29, 2018 included 52 weeks and our fiscal year ending December 28, 2019 includes 52 weeks. The fiscal year ended December 29, 2018 is referred to as “fiscal 2018” and the fiscal year ended December 28, 2019 is referred to as “fiscal 2019”.
  • Net revenue increased by $3.2 million in the fiscal three months ended September 28, 2019 compared to the fiscal three months ended September 29, 2018 primarily as a result of an increase in the number of OCS disposable sets sold to customers globally.
  • Net revenue from customers in the United States was $4.3 million in the fiscal three months ended September 28, 2019 and increased by $2.1 million in the fiscal three months ended September 28, 2019 compared to the fiscal three months ended September 29, 2018. The increase in net revenue from customers in the United States was primarily due to commercial sales of OCS Lung products, sales of OCS disposable sets for use in our OCS Heart EXPAND CAP Trial and OCS Heart DCD Trial and sales of OCS disposable sets to customers for use in our OCS Liver PROTECT Trial. Net revenue from sales of OCS Lung products in the United States increased from $1.3 million in the fiscal three months ended September 29, 2018 to $1.9 million in the fiscal three months ended September 28, 2019. Net revenue from OCS Heart disposable sets sold to customers for use in our OCS Heart EXPAND CAP Trial and OCS Heart DCD Trial increased from $0.0 million in the fiscal three months ended September 29, 2018 to $1.1 million in the fiscal three months ended September 28, 2019.  Net revenue from OCS Liver disposable sets sold to customers for use in our OCS Liver PROTECT Trial increased from $0.9 million in the fiscal three months ended September 29, 2018 to $1.4 million in the fiscal three months ended September 28, 2019. In addition, the U.S. selling price of OCS disposable sets sold in the third quarter of fiscal 2019 was approximately 25% higher than the U.S. selling prices of OCS disposable sets sold in the same period in fiscal 2018, which accounted for $0.8 million of the overall $2.1 million increase in net revenue in the United States from the third quarter of fiscal 2018 to the same period in fiscal 2019.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg

Proxies

No filings